HK inno.N announced on the 7th that its flagship drug, "K-CAB (Tegoprazan), has successfully ended phase 1 clinical trials in the U.S., a treatment for gastroesophageal reflux disease.

The clinical trial was conducted on 30 healthy adults with random assignment, double blinding, placebo control, and repeated administration. K-CAB 25 mg, 50 mg, and 100 mg were administered to clinical participants orally for 7 days, respectively, and pharmacokinetic characteristics and safety were evaluated.

As a result of pharmacokinetic evaluation, the blood concentration of K-CAB was proportional according to the content, and similar profiles were maintained on both the 1st and 7th days of administratio